<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02486640</url>
  </required_header>
  <id_info>
    <org_study_id>18016</org_study_id>
    <secondary_id>BF1502</secondary_id>
    <nct_id>NCT02486640</nct_id>
  </id_info>
  <brief_title>Evaluation of Potential Predictors of Adherence by Investigating a Representative Cohort of Multiple Sclerosis (MS) Patients in Germany Treated With Betaferon</brief_title>
  <acronym>BETAPREDICT</acronym>
  <official_title>BETAPREDICT - MS Patients Treated With BETAferon®: PREDICTors of Treatment Adherence</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to evaluate potential predictors of adherence by investigating a&#xD;
      representative cohort of MS patients in Germany treated with Betaferon&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 8, 2015</start_date>
  <completion_date type="Actual">January 16, 2020</completion_date>
  <primary_completion_date type="Actual">October 31, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Compliance to therapy (%)</measure>
    <time_frame>12 months</time_frame>
    <description>Compliance (%) = ((expected # of treatment days during observation period - missed # of treatment days during observation period)/(expected # of treatment days during observation period))*100</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Persistence of therapy (Yes or No)</measure>
    <time_frame>12 months</time_frame>
    <description>Persistence is defined as patients continuing (&quot;persisting&quot;) their medication (regardless of the frequency of intake)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall adherence to therapy (Yes or No)</measure>
    <time_frame>12 months</time_frame>
    <description>Patients will be defined as being adherent to therapy if they fulfill the following criteria: a. They have been at least 80% compliant, i.e. injected ≥80% of the expected Betaferon dosages and b. They have not dropped out of the study prior to the time of evaluation (i.e. they did not stop Betaferon treatment for any reason including switching to another medication prior to the time of evaluation).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Satisfaction with the BETACONNECT autoinjector, recorded by the patient questionnaire</measure>
    <time_frame>Up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adherence to Betaferon treatment is associated with: depression, health related quality of life, coping mechanisms, self-management mechanisms, social support, fatigue, and cognition. (Yes or No)</measure>
    <time_frame>Up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adherence to Betaferon treatment is associated with number of relapses (Yes or No)</measure>
    <time_frame>12 months, 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adherence to Betaferon treatment is associated with EDSS change (Yes or No)</measure>
    <time_frame>12 months, 24 months</time_frame>
    <description>EDSS (Expanded Disability Status Scale)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adherence to Betaferon treatment is associated with utilities of treatment, recorded by the EQ-5D quality of life questionnaire (Yes or No)</measure>
    <time_frame>Up to 24 months</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">162</enrollment>
  <condition>Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>Betaferon</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Interferon beta-1b (Betaferon, BAY86-5046)</intervention_name>
    <description>Multiple Sclerosis patients who are treated with Betaferon and who are using the Betaconnect autoinjector.</description>
    <arm_group_label>Betaferon</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Betaconnect Autoinjector</intervention_name>
    <description>Multiple Sclerosis patients who are treated with Betaferon and who are using the Betaconnect autoinjector.</description>
    <arm_group_label>Betaferon</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The study population will consist of patients with relapsing remitting multiple sclerosis&#xD;
        (RRMS) or patients with a clinically isolated syndrome (CIS) who are treated with Betaferon&#xD;
        or will be treated with Betaferon according to the attending physician's decision and for&#xD;
        whom the patient and the physician have agreed to use the BETACONNECT device&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients aged ≥ 18 years with the diagnosis of relapsing remitting multiple sclerosis&#xD;
             or a clinically isolated syndrome&#xD;
&#xD;
          -  Patients on treatment with Betaferon or the decision to treat patients with Betaferon&#xD;
             has been made by the attending physician&#xD;
&#xD;
          -  Patients using or willing to use the BETACONNECT autoinjector for Betaferon&#xD;
             application&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients receiving any other disease modifying drug&#xD;
&#xD;
          -  Contraindications of Betaferon described in the Summary of Product Characteristics&#xD;
&#xD;
          -  Patients participating in any other clinical or non-interventional study, evaluating&#xD;
             MS therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Multiple Locations</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>https://clinicaltrials.bayer.com/</url>
    <description>Click here to find results for studies related to Bayer products</description>
  </link>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>June 15, 2015</study_first_submitted>
  <study_first_submitted_qc>June 29, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 1, 2015</study_first_posted>
  <last_update_submitted>January 15, 2021</last_update_submitted>
  <last_update_submitted_qc>January 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>RRMS, CIS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Interferon-beta</mesh_term>
    <mesh_term>Interferon beta-1b</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

